1994
DOI: 10.2169/internalmedicine.33.407
|View full text |Cite
|
Sign up to set email alerts
|

Effect of H2-Receptor Antagonists Cimetidine and Famotidine on Interdigestive Gastric Motor Activity and Lower Esophageal Sphincter Pressure in Progressive Systemic Sclerosis.

Abstract: The effect of the H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure was assessed in 41 patients with uncomplicated progressive systemic sclerosis. There was no significant change in gastric phasic motor activity after the intravenous administration of cimetidine (n=6), famotidine (n=13), and physiological saline (n=15), or the intragastric infusion of 7%sodium bicarbonate (n=7). The lower esophageal sphincter pressure was increase… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2007
2007
2021
2021

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 19 publications
0
6
0
Order By: Relevance
“…In total, 210 articles were evaluated and 73 were ultimately selected for inclusion in this study (refs 6–77,. and Seibold JR et al: unpublished observations).…”
Section: Resultsmentioning
confidence: 99%
“…In total, 210 articles were evaluated and 73 were ultimately selected for inclusion in this study (refs 6–77,. and Seibold JR et al: unpublished observations).…”
Section: Resultsmentioning
confidence: 99%
“…However, only famotidine caused a significant esophageal pressure rise in patients without an increase of gastric motility. These findings suggest that the inhibition of lower esophageal acetylcholinesterase activity and gastric acid secretion may be involved in the mechanisms of action of cimetidine and famotidine (70).…”
Section: Management Of Gastrointestinal Manifestationsmentioning
confidence: 96%
“…Cisapride is another 5HT-4 agonist which has been studied in reflux esophagitis in SSc, but has since been withdrawn from the market due to concern for cardiac arrhythmias (69). Cisapride increases acetylcholine release from the myenteric plexus and is thought to increase lower esophageal sphincter pressure and gastric emptying through increases in esophageal contracting amplitudes and in the number of gastric contractions (70). Another high affinity 5HT-4, prucalopride, is still being studied for pro-motility for chronic intestinal pseudo-obstruction (67), but is not yet approved by the U.S. Food and Drug administration.…”
Section: Management Of Gastrointestinal Manifestationsmentioning
confidence: 99%
“…Unfortunately, only a few prospective studies have assessed GIT in SSc [37,38], and these studies have not led to major advances in development of outcome measures. In other words, although assessment of the GIT in SSc remains a challenge, new approaches are promising.…”
Section: Patient-reported Outcome Measurementioning
confidence: 99%